Sugammadex: A review of its use in anaesthetic practice

Drugs

Volumn 69, Issue 7, 2009, Pages 919-942

  Yang, Lily P H ^a   Keam, Susan J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Selective relaxant binding agent; Sugammadex; Therapeutic use; Tolerability

Indexed keywords

ATROPINE; CISATRACURIUM; EDROPHONIUM; FLUCLOXACILLIN; FUSIDIC ACID; GLYCOPYRRONIUM BROMIDE; NEOSTIGMINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROPOFOL; ROCURONIUM; SALBUTAMOL; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; TERBUTALINE SULFATE; TOREMIFENE; VECURONIUM;

AGE DISTRIBUTION; ANESTHESIA COMPLICATION; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BINDING AFFINITY; BREAST FEEDING; BRONCHOSPASM; CHILL; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSURIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPOTENSION; INJECTION SITE PAIN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; MUSCLE RELAXATION; NAUSEA; NEUROMUSCULAR BLOCKING; NONHUMAN; OBESITY; OPTIMAL DRUG DOSE; PAIN; PROCEDURAL SITE REACTION; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ANDROSTANOLS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 66149146606     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969070-00008     Document Type: Article

References (89)

1. Bowman WC. Neuromuscular block. Br J Pharmacol 2006 Jan; 147 Suppl. 1: S277-86
2. Utting JE. The era of relaxant anaesthesia. Br J Anaesth 1992 Dec; 69 (6): 551-3
3. de Boer HD, van Egmond J, Driessen JJ, et al. Update on the management of neuromuscular block: focus on su- gammadex. Neuropsych Dis Treat 2007; 3 (5): 539-44
4. Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy 2007 Aug; 27 (8): 1181-8
5. Wiklund RA, Rosenbaum SH. Anesthesiology: first of two parts. N Engl J Med 1997 Oct 16; 337 (16): 1132-41
6. Baraka A. Suxamethonium-neostigmine interaction in pa- tients with normal of atypical cholinesterase. Br J Anaesth 1977 May; 49 (5): 479-84
7. Miller RD. Sugammadex: an opportunity to change the prac- tice of anesthesiology?AnesthAnalg 2007Mar; 104 (3): 477-8
8. Magorian T, Flannery KB, Miller RD. Comparison of ro- curonium, succinylcholine, and vecuronium for rapid- sequence induction of anesthesia in adult patients. An- esthesiology 1993 Nov; 79 (5): 913-8
9. Raghavendra T. Neuromuscular blocking drugs: discovery and development. J R Soc Med 2002 Jul; 95 (7): 363-7
10. Karcioglu O, Arnold J, Topacoglu H, et al. Succinylcholine or rocuronium? A meta-analysis of the effects on intuba- tion conditions. Int J Clin Pract 2006 Dec; 60 (12): 1638-46
11. GlaxoSmithKline UK. Anectine injection (suxamethonium chloride): summary of product characteristics [online]. Available from URL: http://emc.medicines. org.uk/emc/ assets/c/html/displayDocPrinterFriendly.asp?documentid= 704 [Accessed 2008 Sep 26]
12. NV Organon. Esmeron® (rocuronium bromide) 10mg/mL solution for injection: summary of product characteristics [on- line]. Available from URL: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinterFriendly.asp? documentid= 5166 [Accessed 2008 Oct 9]
13. Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009 Mar; 24 (1): 21-8
14. Donati F. Sugammadex: an opportunity for more thinking or more cookbook medicine? Can J Anesth 2007 Sep; 54 (9): 689-95
15. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activ- ity relationships. J Med Chem 2002 Apr 25; 45 (9): 1806-16
16. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan 18; 41 (2): 266-70
17. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceu- tical applications. Int J Pharm 2007 Feb 1; 329 (1-2): 1-11
18. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008; 36 (1): 30-42
19. Challa R, Ahuja A, Ali J, et al. Cyclodextrins in drug de- livery: an updated review. AAPS PharmSciTech 2005 Oct 14; 6 (2): E329-57
20. Schering-Plough Corp. Bridion® (sugammadex sodium) injection: first and only selective relaxant binding agent ap- proved in European Union [online]. Available from URL: http://www.schering-plough.com/schering-plough/news/ release.jsp?releaseID=1180933 [Accessed 2008 Aug 20]
21. ZhangM-Q. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003 Apr; 28 (4): 347-54
22. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel re- versal agent Org 25969. Anesthesiology 2003 Sep; 99 (3): 632-7
23. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: effi- cacy, safety, and pharmacokinetics. Anesthesiology 2007 May; 106 (5): 935-43
24. Epemolu O, Mayer I, Hope F, et al. Liquid chrom- atography/mass spectrometric bioanalysis of a modified g-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002; 16 (20): 1946-52
25. de Boer HD, van Egmond J, van de Pol F, et al. Sugamma- dex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006 Apr; 96 (4): 473-9
26. Groudine SB, Soto R, Lien C, et al. A randomized, dose- finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104 (3): 555-62
27. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for an- tagonism of prolonged rocuronium-induced neuromus- cular block. Br J Anaesth 2006 Jan; 96 (1): 36-43
28. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104 (4): 667-74
29. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromus- cular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 Feb; 106 (2): 283-8
30. Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008 Aug; 109 (2): 188-97
31. de Boer HD, Driessen JJ, Marcus MAE, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107 (2): 239-44
32. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005 Oct; 103 (4): 695-703
33. Vanacker BF, Vermeyen KM, Struys MMR, et al. Reversal of rocuronium-induced neuromuscular block with the no- vel drug sugammadex is equally effective under main- tenance anesthesia with propofol or sevoflurane. Anesth Analg 2007 Mar; 104 (3): 563-8
34. Wagner S, Pühringer FK, Spies C, et al. Sugammadex reverses neuromuscular blockade after continuous infusion of rocuronium in patients under sevoflurane or propofol maintenance anesthesia [abstract no. S218]. Anesth Analg 2008 Mar; 106 Suppl. 3: S218
35. European Medicines Agency. Bridion (sugammadex sodium) 100mg/mL: summary of product characteristics [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/bridion/H-885-PI-en.pdf [Ac- cessed 2009 Feb 5]
36. deKamP-J, vanKuijk J, Smeets J, et al. Single IV sugamma- dex doses up to 32mg/kg are not associated with QT/QTc prolongation [abstract no. A1580]. 2007 AnnualMeeting of the American Society of Anesthesiologists; 2007 Oct 13-17; San Francisco (CA)
37. de Kam P, van Kuijk J, Prohn M, et al. Single IV su- gammadex doses up to 32mg/kg alone or in combination with rocuronium or vecuronium are not associated with QTc prolongation [abstract no. 9AP5-9]. Eur J Anaes- thesiol 2008 Jun; 25 Suppl. 44: 9AP5-9. Plus poster pre- sented at the 2008 AnnualMeeting of the European Societyof Anaesthesiology; 2008 May 31-Jun 3; Copenhagen
38. Organon USA. FDA Anesthetic and Life Support Advisory Committee Meeting: briefing document (background pack- age) for sugammadex sodium injection [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/brief- ing/2008-4346b1-02-Organon.pdf [Accessed 2008 Oct 2]
39. Fuchs-Buder T, Schreiber J-U, Meistelman C. Monitoring neuromuscular block: an update. Anaesthesia 2009 Mar; 64 Suppl. 1: 82-9
40. American Society of Anesthesiologists. ASA physical status classification system [online]. Available from URL: http:// www.asahq.org/clinical/ physicalstatus.htm [Accessed 2008 Sep 26]
41. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Hu- man Use. The clinical evaluation of QT/QTc interval prolong- ation and proarrhythmic potential for non-antiarrhythmic drugs: E14 [online]. Available from URL: http://www.ich. org/LOB/media/MEDIA1476.pdf [Accessed 2009 Apr 6]
42. Dahl V, Pendeville PE, Hollman MW, et al. Reversal of rocuronium-induced neuromuscular blockade by sugamma- dex in cardiac patients [abstract no. A1581 plus poster]. 2007 Annual Meeting of the American Society of An- esthesiologists; 2007 Oct 13-17; San Francisco (CA)
43. Eikermann M, Zaremba S, Malhotra A, et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008 Sep; 101 (3): 344-9
44. Staals L, Snoeck M, Hunter J, et al. Pharmacokinetics of rocuronium and sugammadex in patients with normal and impaired renal function [abstract plus poster]. 14th World Congress of Anaesthesiologists; 2008Mar 2-7; Cape Town
45. Khuenl-Brady KS, Sparr H. Clinical pharmacokinetics of rocuroniumbromide. Clin Pharmacokinet 1996 Sep; 31 (3): 174-83
46. Sparr HJ, Beaufort TM, Fuchs-Buder T. Newer neuromus- cular blocking agents: how do they compare with estab- lished agents? Drugs 2001; 61 (7): 919-42
47. Proost JH, Eriksson LI,Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J An- aesth 2000 Nov; 85 (5): 717-23
48. Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, par- allel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008 Oct; 101 (4): 492-7
49. Plaud B, Meretoja O, Hofmockel R, et al. Reversal of ro- curonium-induced neuromuscular blockade with sugamma- dex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110 (2): 284-94
50. Blobner M, Eriksson L, Scholz J, et al. Sugammadex (2.0mg/kg) significantly faster reverses shallow rocuronium- induced neuromuscular blockade compared with neostigmne (50mg/kg) [abstract no. 9AP7-10]. Eur J Anaesthesiol 2007 Jun; 24: 125. Plus poster presented at the 2007 Congress of the European Society of Anaesthesiology; 2007 Jun 9-12;Munich
51. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugamma- dex is faster than reversal of cisatracurium-induced blockwith neostigmine. Br J Anaesth 2008 May; 100 (5): 622-30
52. Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a ran- domized comparison with neostigmine. Anesthesiology 2008 Nov; 109 (5): 816-24
53. Lee C, Jahr JS, CandiottiKA, et al.Reversal of profound neuro- muscular block by sugammadex administered 3 minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009 May; 110 (5): 1020-5
54. Alvarez-Gomez JA, WattwillM, Vanacker B, et al. Reversal of vecuronium-induced shallow neuromuscular blockade is signi- ficantly faster with sugammadex compared with neostigmine [abstract no. 9AP7-8]. Eur J Anaesthesiol 2007 Jun; 24 Suppl. 39: 124-5. Plus poster presented at the 2007 Congress of the European Society of Anaesthesiology; 2007 Jun 9-12; Munich
55. Lemmens HJM, El-Orbany MI, Berry J, et al. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine [abstract no. A1578 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13-17; San Francisco (CA)
56. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edro- phonium-atropine. Anesth Analg 2007Mar; 104 (3): 569-74
57. Pavlin EG, White PF, Viegas OJ, et al. Sugammadex given at least 15min after rocuronium is effective in reversing neuromuscular blockade [abstract no. A1579 plus poster]. 2007 Annual Meeting of the American Society of An- esthesiologists; 2007 Oct 13-17; San Francisco (CA)
58. McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients [abstract no. A1583 plus pos- ter]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13-17; San Francisco (CA)
59. Amao R, Zornow MH, McTaggart Cowan R, et al. Sugammadex safely reverses rocuronium-induced block- ade in patients with pulmonary disease [abstract no. A1582 plus poster]. 2007 AnnualMeeting of the American Societ of Anesthesiologists; 2007 Oct 13-17; San Francisco (CA)
60. Monk TG, Rietbergen H, Woo T. Obesity has no clinically relevant impact upon recovery time following administra-ion of sugammadex [abstract no. A682 plus poster]. 2008 Annual Meeting of the American Society of Anesthesiolo- ists; 2008 Oct 18-22; Orlando (FL)
61. Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007 Aug; 51 (7): 789-808
62. Cammu G, De Kam PJ, Demeyer I, et al. Safety and toler- ability of single intravenous doses of sugammadex ad- ministered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008Mar; 100 (3): 373-9
63. Peeters P, Passier P, Smeets J, et al. Single intravenous high- dose sugammadex (up to 96mg/kg) is generally safe and well tolerated in healthy volunteers [abstract no. 9AP3-6]. Eur J Anaesthesiol 2008; 25 Suppl. 4: 9AP3-6. Plus poster presented at the 2008 Congress of the European Society of Anaesthesiology; 2008 May 31-Jun 3; Copenhagen
64. Molina AL, de Boer HD, Klimek M, et al. Reversal of rocuronium-induced (1.2mg kg-1) profound neuromus- cular block by accidental high dose of sugammadex (40mg kg-1). Br J Anaesth 2007 May; 98 (5): 624-7
65. European Medicines Agency. European Public Assessment Re- port for Bridion (sugammadex): scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/bridion/H-885-en6.pdf [Accessed 2008 Oct 1]
66. Plaud B, van Heumen E, Zwiers A. Sugammadex is well tol- erated for the reversal of rocuronium- or vecuronium- induced neuromuscular blockade in a pooled analysis of adverse events in 10 placebo-controlled trials [abstract no. 9AP3-3]. Eur JAnaesthesiol 2008; 25 Suppl. 44: 9AP3-3. Plus poster presented at the 2008 Congress of the European So- ciety of Anaesthesiology; 2008May 31-Jun 3; Copenhagen
67. Mattila K, Toivonen J, Janhunen L, et al. Postdischarge symp- toms after ambulatory surgery: first-week incidence, intensity, and risk factors. Anesth Analg 2005 Dec; 101 (6): 1643-50
68. Weiser TG, Regenbogen SE, Thompson KD, et al. An esti- mation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008 Jul 12; 372 (9633): 139-44
69. Donati F. Sugammadex: a cyclodextrin to reverse neuro- muscular blockade in anaesthesia. Expert Opin Pharmac- other 2008 May; 9 (8): 1375-86
70. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003 May; 98 (5): 1037-9
71. Debaene B, Plaud B, Dilly M-P, et al. Residual paralysis in the PACU after a single intubating dose of nondepolariz- ing muscle relaxant with an intermediate duration of ac- tion. Anesthesiology 2003 May; 98 (5): 1042-8
72. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol 2006 Mar; 72 (3): 97-109
73. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006 Aug; 97 (2): 123-6
74. Miller RD. Antagonism of neuromuscular blockade. An- esthesiology 1976 Apr; 44 (4): 318-29
75. Naguib M, Kopman AF, Ensor JE. Neuromuscular mon- itoring and postoperative residual curarization: a meta- analysis. Br J Anaesth 2007 Mar; 98 (3): 302-16
76. Murphy GS, Szokol JW,Marymont JH, et al. Residual neuro- muscular blockade and critical respiratory events in the post- anesthesia care unit. Anesth Analg 2008 Jul; 107 (1): 130-7
77. Arbous MS, Meursing AEE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005 Feb; 102 (2): 257-68
78. Kopman AF, Eikermann M. Antagonism of non-depolar- ising neuromuscular block: current practice. Anaesthesia 2009 Mar; 64 Suppl. 1: 22-30
79. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007 Mar; 04 (3): 575-81
80. Harris AM, Welliver M, Redfern R, et al. Orthopaedic surgery implications of a novel encapsulation process that improves neuromuscular blockade and reversal. Internet J Orthop Surg 2007; 7 (2): e1-12
81. Reid JE, Breslin DS, Mirakhur RK, et al. Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. Can J Anesth 2001 Apr; 48 (4): 351-5
82. Mirakhur RK. Sugammadex in clinical practice. Anaes- thesia 2009 Mar; 64 Suppl. 1: 45-54
83. Duvaldestin P, Kuizenga K, Kjaer CC, et al. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose- response study [abstract no. 9AP7-3]. Eur J Anaesthesiol 2007 Jun; 24: 123. Plus poster presented at the 2007 Congress of the European Society of Anaesthesiology; 2007 Jun 9-12; Munich
84. Levano S, Ginz H, Siegemund M, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuro- muscular block after succinylcholine. Anesthesiology 2005 Mar; 102 (3): 531-5
85. Brull SJ. Patient safety revisited: reliability is paramount. Anesth Analg 2009 Mar; 108 (3): 702-3
86. White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of re- versal with sugammadex. Anesth Analg 2009Mar; 108 (3): 846-51
87. Perry JJ, Lees JS, Sillberg VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008 Apr 16; 16 (2): CD002788
88. Zhang B,Menzin J, TranMH, et al. The potential savings in operating room time associated with the use of sugamma- dex to reverse selected neuromuscular blocking agents: findings from a hospital efficiency model [abstract no. PHC9]. Value Health 2008 May-Jun; 11 (3): A244
89. Schering-Plough Corp. US FDA issues action letter for sugammadex [online]. Available from URL: http:// www.schering-plough.com/schering-plough/ news/release. jsp?releaseID=1182475 [Accessed 2008 Aug 20]